Host cholesterol and inflammation as common key regulators of toxoplasmosis and artherosclerosis development

References

• Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially Toll-like receptor 2, on murine atherosclerosis. Curr. Drug Targets8(12), 1230–1238 (2007).
   PubMed Web of Science ®Google Scholar
• Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology58(5), 513–522 (2007).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev.65(12 Pt 2), S140–S146 (2007).
   PubMed Web of Science ®Google Scholar
• Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol.8(10), 802–815 (2008).
   PubMed Web of Science ®Google Scholar
• von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res.100(1), 27–40 (2007).
   PubMed Web of Science ®Google Scholar
• Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med.122(1 Suppl.), S3–S14 (2009).
   PubMed Web of Science ®Google Scholar
• Insull W Jr. Introduction. Review of major recent findings supporting treatments to control advanced plaques of atherosclerosis. Am. J. Med.122(1 Suppl.), S1–S2 (2009).
   PubMedGoogle Scholar
• Olofsson KE, Björkbacka H. Atherosclerosis: cell biology and lipoproteins. Curr. Opin. Lipidol.20, 82–84 (2009).
   PubMedGoogle Scholar
• Kaski JC. Infection, endothelial dysfunction, and atherogenesis. Circulation108(25), E171–E172; author reply E171–E172 (2003).
   PubMedGoogle Scholar
• Muhlestein JB, Anderson JL. Chronic infection and coronary artery disease. Cardiol. Clin.21(3), 333–362 (2003).
   PubMedGoogle Scholar
• Kaski JC. Infection, endothelial dysfunction, and atherogenesis. Circulation108(25), E171–E172; author reply E171–E172 (2003).
   PubMedGoogle Scholar
• Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol. Rep.60(1), 85–92 (2008).
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Hamada M, Otaguro S et al. Chronic Helicobacter pylori infection is associated with peripheral arterial disease. J. Infect. Chemother.14(3), 250–254 (2008).
   PubMedGoogle Scholar
• Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis199(1), 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Chen S, Sorrentino R, Shimada K et al.Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J. Immunol.181(10), 7186–7193 (2008).
   PubMed Web of Science ®Google Scholar
• Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C. Chlamydia pneumoniae and vascular disease: an update. J. Vasc. Surg.43(6), 1301–1307 (2006).
   PubMedGoogle Scholar
• Niedzielska I, Janic T, Cierpka S, Swietochowska E. The effect of chronic periodontitis on the development of atherosclerosis: review of the literature. Med. Sci. Monit.14(7), RA103–RA106 (2008).
   PubMed Web of Science ®Google Scholar
• Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol.24, 239–252 (2000).
   Google Scholar
• Turkay C, Saba R, Sahin N et al. Effect of chronic Pseudomonas aeruginosa infection on the development of atherosclerosis in a rat model. Clin. Microbiol. Infect.10(8), 705–708 (2004).
   PubMed Web of Science ®Google Scholar
• Monteiro AM, Jardini MA, Alves S et al. Cardiovascular disease parameters in periodontitis. J. Periodontol.80(3), 378–388 (2009).
   PubMed Web of Science ®Google Scholar
• Prediman K, Shah MD. Link Between infection and atherosclerosis: who are the culprits: viruses, bacteria, both, or neither? Circulation103, 5–6 (2001).
   PubMedGoogle Scholar
• Ciervo A, Mancini F, Sale P, Russo A, Cassone A. Real-time polymerase chain reaction and laser capture microdissection: an efficient combination tool for Chlamydophila pneumoniae DNA quantification and localization of infection in atherosclerotic lesions. Int. J. Immunopathol. Pharmacol.21(2), 421–428 (2008).
   PubMedGoogle Scholar
• Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLoS ONE3(9), e3204 (2008).
   PubMed Web of Science ®Google Scholar
• Sunnemark D, Frostegard J, Orn A, Harris RA. Cellular and cytokine characterization of vascular inflammation in CBA/J mice chronically infected with Trypanosoma cruzi. Scand. J. Immunol.48(5), 480–484 (1998).
   PubMedGoogle Scholar
• Sunnemark D, Harris RA, Frostegard J, Orn A. Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and high cholesterol diet. Atherosclerosis153, 273–282 (2000).
   PubMedGoogle Scholar
• Portugal LR, Fernandes LR, Cesar GC et al. Infection with Toxoplasma gondii increases atherosclerotic lesion in ApoE-deficient mice. Infect. Immun.72(6), 3571–3576 (2004).
   PubMedGoogle Scholar
• Portugal LR, Fernandes LR, Pietra Pedroso VS, Santiago HC, Gazzinelli RT, Alvarez-Leite JI. Influence of low-density lipoprotein (LDL) receptor on lipid composition, inflammation and parasitism during Toxoplasma gondii infection. Microbes Infect.10(3), 276–284 (2008).
   PubMedGoogle Scholar
• Fernandes LR. Influence of Leishmania major infection on lipid profile and atherogenesis in Apo E deficient mice. In: Biochemistry and Immunology. Federal University of Minas Gerais, Belo Horizonte, Brazil 90 (2006).
   Google Scholar
• Golgher D, Gazzinelli RT. Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity37(5), 399–409 (2004).
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Talvani A, Camargo MM et al. Induction of cell-mediated immunity during early stages of infection with intracellular protozoa. Braz. J. Med. Biol. Res.31, 89–104 (1998).
   PubMedGoogle Scholar
• Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am. J. Pathol.172(6), 1500–1508 (2008).
   PubMed Web of Science ®Google Scholar
• Shibata Y, Ohata H, Yamashita M et al. Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette–Guérin (BCG)-treated apolipoprotein E-knockout (Apo E-/-) mice. Transl. Res.149(2), 62–69 (2007).
   PubMedGoogle Scholar
• Zenovich AG, Panoskaltsis-Mortari A, Caron GJ et al. Sex-based differences in vascular repair with bone marrow cell therapy: relevance of regulatory and Th2-type cytokines. Transplant Proc.40(2), 641–643 (2008).
   PubMedGoogle Scholar
• Doenhoff MJ, Stanley RG, Griffiths K, Jackson CL. An anti-atherogenic effect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol. Parasitology125(Pt 5), 415–421 (2002).
   PubMedGoogle Scholar
• Assaad-Khalil SH, Lachine N, Sidrak M, Amara F, Jacotot B, Fahmy MH. Immuno-metabolic factors in schistosomal hepatic fibrosis modulating atherogenesis. Ann. Biol. Clin. (Paris)50(10–11), 697–701 (1992).
   PubMedGoogle Scholar
• La Flamme AC, Ruddenklau K, Backstrom BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect. Immun.71(9), 4996–5004 (2003).
   PubMed Web of Science ®Google Scholar
• Sewell D, Qing Z, Reinke E et al. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int. Immunol.15(1), 59–69 (2003).
   PubMed Web of Science ®Google Scholar
• La Flamme AC, Harvie M, Kenwright D et al. Chronic exposure to schistosome eggs reduces serum cholesterol but has no effect on atherosclerotic lesion development. Parasite Immunol.29(5), 259–266 (2007).
   PubMedGoogle Scholar
• Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology50(5), 535–546 (2007).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352(16), 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature451(7181), 904–913 (2008).
   PubMed Web of Science ®Google Scholar
• Kume N, Kita T. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr. Opin. Lipidol.12, 419–423 (2001).
   PubMed Web of Science ®Google Scholar
• Minami M, Kume N, Shimaoka T et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human athero-sclerotic lesions. Arterioscler. Thromb. Vasc. Biol.21, 1796–1800 (2001).
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Uematsu S, Akira S. ‘Toll’ gates for future immunotherapy. Curr. Pharm. Des.12(32), 4135–4142 (2006).
   PubMed Web of Science ®Google Scholar
• Oude Nijhuis MM, van Keulen JK, Pasterkamp G, Quax PH, de Kleijn DP. Activation of the innate immune system in atherosclerotic disease. Curr. Pharm. Des.13(10), 983–994 (2007).
   PubMed Web of Science ®Google Scholar
• Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc. Med.18(2), 52–56 (2008).
   PubMed Web of Science ®Google Scholar
• Mullick AE, Soldau K, Kiosses WB, Bell TA 3rd, Tobias PS, Curtiss LK. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J. Exp. Med.205(2), 373–383 (2008).
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest.115(11), 3149–3156 (2005).
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol. Res.34(3), 193–209 (2006).
   PubMed Web of Science ®Google Scholar
• Tobias P, Curtiss LK. Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: Toll receptors in atherogenesis. J. Lipid Res.46(3), 404–411 (2005).
   PubMed Web of Science ®Google Scholar
• Tobias PS, Curtiss LK. Toll-like receptors in atherosclerosis. Biochem. Soc. Trans.35(Pt 6), 1453–1455 (2007).
   PubMed Web of Science ®Google Scholar
• Tobias PS, Curtiss LK. TLR2 in murine atherosclerosis. Semin. Immunopathol.30(1), 23–27 (2008).
   PubMedGoogle Scholar
• Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation105(10), 1158–1161 (2002).
   PubMed Web of Science ®Google Scholar
• Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation118(12), 1276–1284 (2008).
   PubMed Web of Science ®Google Scholar
• Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation104, 3103–3108 (2001).
   PubMed Web of Science ®Google Scholar
• Vink A, Schoneveld AH, van der Meer JJ et al.In vivo evidence for a role of Toll-like receptor 4 in the development of intimal lesions. Circulation106(15), 1985–1990 (2002).
   PubMed Web of Science ®Google Scholar
• Ranjbaran H, Sokol SI, Gallo A et al. An inflammatory pathway of IFN-γ production in coronary atherosclerosis. J. Immunol.178(1), 592–604 (2007).
   PubMedGoogle Scholar
• Aukrust P, Otterdal K, Yndestad A et al. The complex role of T-cell-based immunity in atherosclerosis. Curr. Atheroscler. Rep.10(3), 236–243 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang H, Park Y, Wu J et al. Role of TNF-α in vascular dysfunction. Clin. Sci. (Lond.)116(3), 219–230 (2009).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol.8, 345–350 (2007).
   PubMed Web of Science ®Google Scholar
• Patel DN, King CA, Bailey SR. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-κB and C/EBPβ activation. J. Biol. Chem.282, 27229–27238 (2007).
   PubMed Web of Science ®Google Scholar
• Eid RE, Rao DA, Zhou J et al. Interleukin-17 and interferon-γ are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation119(10), 1424–1432 (2009).
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Ropert C, Campos MA. Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol. Rev.201, 9–25 (2004).
   PubMed Web of Science ®Google Scholar
• Yarovinsky F, Zhang D, Andersen JF et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science308(5728), 1626–1629 (2005).
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Denkers EY. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat. Rev. Immunol.6(12), 895–906 (2006).
   PubMed Web of Science ®Google Scholar
• Yarovinsky F. Toll-like receptors and their role in host resistance to Toxoplasma gondii. Immunol. Lett.119(1–2), 17–21 (2008).
   PubMedGoogle Scholar
• Yarovinsky F, Hieny S, Sher A. Recognition of Toxoplasma gondii by TLR11 prevents parasite-induced immunopathology. J. Immunol.181(12), 8478–8484 (2008).
   PubMedGoogle Scholar
• Debierre-Grockiego F, Campos MA, Azzouz N et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J. Immunol.179(2), 1129–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Debierre-Grockiego F, Azzouz N, Schmidt J et al. Roles of glycosylphosphatidylinositols of Toxoplasma gondii. Induction of tumor necrosis factor-α production in macrophages. J. Biol. Chem.278(35), 32987–32993 (2003).
   PubMedGoogle Scholar
• Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int. J. Parasitol.39(8), 895–901 (2009).
   PubMed Web of Science ®Google Scholar
• Kim K, Weiss LM. Toxoplasma: the next 100 years. Microbes Infect.10(9), 978–984 (2008).
   PubMedGoogle Scholar
• Aliberti J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat. Rev. Immunol.5(2), 162–170 (2005).
   PubMed Web of Science ®Google Scholar
• Sehgal A, Bettiol S, Pypaert M et al. Peculiarities of host cholesterol transport to the unique intracellular vacuole containing Toxoplasma. Traffic6(12), 1125–1141 (2005).
   PubMedGoogle Scholar
• Coppens I, Vielemeyer O. Insights into unique physiological features of neutral lipids in Apicomplexa: from storage to potential mediation in parasite metabolic activities. Int. J. Parasitol.35(6), 597–615 (2005).
   PubMedGoogle Scholar
• Besteiro S, Bertrand-Michel J, Lebrun M, Vial H, Dubremetz JF. Lipidomic analysis of Toxoplasma gondii tachyzoites rhoptries: further insights into the role of cholesterol. Biochem. J.415(1), 87–96 (2008).
   PubMedGoogle Scholar
• Coppens I. Contribution of host lipids to Toxoplasma pathogenesis. Cell Microbiol.8(1), 1–9 (2006).
   PubMedGoogle Scholar
• Wenk MR. Lipidomics of host–pathogen interactions. FEBS Lett.580(23), 5541–5551 (2006).
   PubMed Web of Science ®Google Scholar
• D’Avila H, Maya-Monteiroa CM, Bozza PT. Lipid bodies in innate immune response to bacterial and parasite infections. Int. Immunopharmacol.8, 1308–1315 (2008).
   PubMed Web of Science ®Google Scholar
• Sonda S, Hehl AB. Lipid biology of Apicomplexa: perspectives for new drug targets, particularly for Toxoplasma gondii. Trends Parasitol.22(1), 41–47 (2006).
   PubMedGoogle Scholar
• Charron AJ, Sibley LD. Host cells: mobilizable lipid resources for the intracellular parasite Toxoplasma gondii. J. Cell. Sci.115(Pt 15), 3049–3059 (2002).
   PubMedGoogle Scholar
• Goldstein JL, Brown MS. The LDL receptor. Arterioscler. Thromb. Vasc. Biol.29(4), 431–438 (2009).
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest.109, 1125–1131 (2002).
   PubMed Web of Science ®Google Scholar
• Coppens I, Joiner KA. Host but not parasite cholesterol controls Toxoplasma cell entry by modulating organelle discharge. Mol. Biol. Cell.14(9), 3804–3820 (2003).
   PubMedGoogle Scholar
• Coppens I, Sinai AP, Joiner KA. Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J. Cell. Biol.149(1), 167–180 (2000).
   PubMed Web of Science ®Google Scholar
• Nishikawa Y, Quittnat F, Stedman TT et al. Host cell lipids control cholesteryl ester synthesis and storage in intracellular Toxoplasma. Cell Microbiol.7(6), 849–867 (2005).
   PubMedGoogle Scholar
• Bansal D, Bhatti HS, Sehgal R. Role of cholesterol in parasitic infections. Lipids Health Dis.4(1), 10 (2005).
   PubMedGoogle Scholar
• Lige B, Jayabalasingham B, Zhang H, Pypaert M, Coppens I. Role of an ancestral D-bifunctional protein containing two sterol-carrier protein-2 domains in lipid uptake and trafficking in Toxoplasma. Mol. Biol. Cell.20(2), 658–672 (2009).
   PubMedGoogle Scholar
• Sonda S, Ting LM, Novak S et al. Cholesterol esterification by host and parasite is essential for optimal proliferation of Toxoplasma gondii. J. Biol. Chem.276(37), 34434–34440 (2001).
   PubMedGoogle Scholar
• Sleat DE, Wiseman JA, El-Banna M et al. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc. Natl Acad. Sci. USA101, 5886–5891 (2004).
   PubMed Web of Science ®Google Scholar
• Lobzin I, Bĭtsov SA, Filippov AE, Linchak RM, Mangutov DA. Effect of respiratory infections on the clinical course of coronary artery disease. Klin. Med. (Mosk.)83(11), 22–26 (2005).
   PubMedGoogle Scholar
• Choudhury RP, Carrelli AL, Stern JD et al. Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J. Vasc. Res.41(1), 75–83 (2004).
   PubMedGoogle Scholar
• Fu T, Borensztajn J. Simvastatin causes the formation of cholesterol-rich remnants in mice lacking apoE. Biochem. Biophys. Res. Commun.341(4), 1172–1176 (2006).
   PubMedGoogle Scholar
• Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res.97(9), 922–927 (2005).
   PubMed Web of Science ®Google Scholar